Teva Pharmaceutical Industries Ltd. ADR 1.14% $25.35B ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of £16.90. The company’s shares closed today at p1,321. ...

Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...

Days after Merck & Co. posted a disappointing result on patient survival from its PD-1/PARP combination of Keytruda and Lynparza in ovarian cancer, GSK delivered a similar message for its Jemperli ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at p1,388.50. Pick the best stocks and maximize ...

GSK has terminated a phase 1/2 hepatitis B trial after the therapeutic vaccine regimen failed to meet the efficacy endpoint, denting the company’s hopes of creating a functional cure for the ...

(Reuters) -China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles vaccine in China, the UK drugmaker said on Thursday, lower than ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...

(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. Read More ...